| Name | Title | Contact Details |
|---|
Tykes & Teens was established in 1996 with the goal of strengthening local families by ensuring that all children have access to high quality counseling and mental health services, regardless of financial status. The agency provides a comprehensive range of programming in Martin, St. Lucie, Indian River and Okeechobee counties.
Boehringer Ingelheim Vetmedica, Inc., a subsidiary of Boehringer Ingelheim Corporation since 1981, is headquartered in St. Joseph, MO. From four sites, St. Joseph, MO, Elwood, KS, Sioux Center, IA, and Ames, IA, this USA subsidiary acts as a center of
Stemedica Cell Technologies, Inc., a biopharmaceutical company, engages in the development and manufacture of adult stem cells and stem cell factors for research institutions and hospitals for pre-clinical and clinical studies. The company was incorporated in 2005 and is based in San Diego, California with a subsidiary location in Lausanne, Switzerland.
Heartland Regional Medical Center is offering patients and physicians in southern Illinois access to the latest diagnositc imaging technology. Our 64 Slice CT (computed tomography) scanner produces crisp, detailed images of the body in just seconds. Our
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.